Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Devyser Diagnostics, Audiocast with teleconference, Q1'24

By Inderes5/8/2024, 7:00 AM
Devyser Diagnostics

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Fredrik Alpsten
00:00 - 11:59

Thank you for that. And again, welcome to the Devyser. Q1 2024 Earnings Call. It's a great pleasure to have you all here. And as I said, today you will hear from me. Fredrik Alpsten, the Devyser CEO, and our chief commercial officer, Theis Kipling. I have also asked our CFO, Sabina Berlin, to join us during the Q&A session. Before we get into our Q1 numbers and talk about the positive development we are seeing. I want to take five minutes to recap what Devyser is for our new and potential new shareholders. Devyser is becoming increasingly well-known as a reliable provider of high-quality next-generation sequencing reagents. We are experiencing high growth through our innovative products and collaborations with industry giants like Thermo Fisher and Illumina. Our name and brand are gaining a lot of additional recognition. The company was founded and is driven by the value of fast and accurate diagnostics. It's the foundation for everything we do to ensure every patient has access to the correct diagnosis in the shortest possible time. Genetic tests can still require a very long time for patients before they get their results, causing worry and potential harm. Ultimately, we aim to enable faster response times for genetic tests and early detection of diseases to help people live healthier and longer lives. More than 100,000 people tested our products in Q1 2024. That is something I, and my colleagues, are very proud of. Devyser is on a journey. As you may know, we have experienced significant development over the last few years, including average organic revenue growth of 36% per year, gross margins well above 80%, the launch of many innovative products, and commercial expansions, both by setting up a direct sales organization and entering into collaborations with some of the most successful global companies. However, we are confident that we are at the beginning of a fantastic journey. Over the last 9 to 12 months, we have taken some very important steps to build a global, fast-growing, highly profitable diagnostic company. Our mission is to be the pioneering leader of diagnostic solutions providing fast, accurate, and easy-to-use solutions to labs worldwide. Our vision is a world where personalized medicine is universally available thanks to simplified and reliable genetic tests. So, what do we do? We develop and market genetic test solutions for targeted cancer therapies. We first take notice of hereditary diseases and post-transplant follow-ups. All development and manufacturing take place in-house at our facility in Stockholm. We sell our products, including probes, peptides, and software, to clinical diagnostic labs via our own sales reps. And we are partners. Or we are distributors. We aim to provide test services to labs and pharmaceutical companies. They have developed and launched more than 35 IVD and IVDR registered products. Interacting in three diagnostic areas: hereditary diseases, oncology, and post-transplantation. We're based here in Stockholm, but we have subsidiaries and sales offices in eight countries, plus a CLIA-certified laboratory in Atlanta, Georgia. We have around 120 employees. Our customers select Devyser because we provide simple, accurate and efficient genetic testing solutions. Our kits and software are easy to implement, maintain, and use for the laboratories. This has to be the foundation for all of our successful growth, because we design our products with a deep understanding of the clinical laboratory workflow and put the genetic laboratory team in focus. Recorded this in over 65 countries, the countries in blue on the map. We have four sales channels: direct sales, partners, our club, and distributors. You will hear more about that a bit later on in the presentation where Theis will cover that. Today we sell directly in some 15 countries, all in Europe and North America. We currently have one partner, Thermo Fisher Scientific, selling our transportation products exclusively in North America, Europe, Brazil, and Saudi Arabia. We have 50 plus distributors that are selling our products in some 50 countries. Our CLIA lab in Atlanta offers testing services to some of us for some of our products for the US market, and it also offers testing services to pharmaceutical and diagnostic companies. Europe is still our dominating market, with 88% of total sales for the last 12 months. America is, however, growing fast. 9% of total sales in the last 12 months, compared with 3% the year before. Africa is still a rather small area for us with only 3% of total sales. For the last 12 months, 75% of revenue came from direct sales, including the club, and 25% from distributors' sales, including the sales departments. The growth in the company is high. I would say even very high. Organic growth has been 36% on average since 2015. That despite a big hiccup in 2020 due to COVID. We reached 180 million MSEK in revenue for the last 12 months. So let's move over and talk about the third quarter. Sales developed well during the quarter and amounted to 51,006, a new record. The earlier record was from Q3 2023, when we reached 47,006. Sales growth, consisting entirely of organic growth, was 28.5% sequentially and 27.7% in local currency. Although these are high numbers, we are optimistic about increasing the growth rate even more in the future. Future growth in some of the direct markets in Europe and the distribution markets in Asia was lower than expected during the quarter. You're approved by 22%. While Asia experienced negative development, primarily due to uneven purchasing patterns from our distributors. However, we assess that Europe's modest growth is only temporary. The strong development we saw in 2023 for Europe should soon return, as several of the important steps we took in 2022 and 2023 materialize fully. You also see the negative development in Asia as temporary. During the last 12 to 18 months, we have concluded several distributor contracts in Asia, and the expectation is that these will start generating sales in the second half of 2024. Most gratifying is that the growth in North and South America continues to be strong. The first quarter showed a sales increase of 291%, although from a low level, of course, our main focus in 2024 and 2025 will be in North America and Europe. We will continue to expand and strengthen our market share in both markets. Expect continued strong growth from these regions in the future as well. Our product areas are growing strongly, particularly our transportation products. It continues to develop very well. The gross margin amount is, sorry. The gross margin jumped to 82.7%, compared with 85.2% in the same quarter last year. The lower gross margin can primarily be attributed to increased production capacity, built up to take advantage of our business opportunities and meet future expected volume increases. Significant investment has been made both in production capacity and in new employees. However, we are positive about the gross margin developments over time, partly because we have a scalable, modern manufacturing process where the increased volume will soon absorb the increased fixed costs. And partly because we still have the opportunity to increase our prices continuously. Results for the quarter were in line with our expectations. The EBIT increased to -$12.2 million, compared with -$19.1 million in the same quarter last year. As announced in the report for the third quarter of 2023. Our move to new premises has entailed some extra costs that burden the fourth quarter of 2023 and to some extent, the first quarter of 2024. Despite this, the operating expenses in the first quarter compared with the first quarter of 2023 only increased by 9.7%. We are convinced that the positive earnings development we saw in 2023 will continue and that we will reach our financial goal of an EBIT margin exceeding 20% during the period 2024 to 2026. Devyser has a very strong financial position, with 250 million MSEK in cash at the end of the quarter and no interest-bearing debts as we have moved to a new facility. We have invested quite a lot in our production capacity during the quarter. The investments in production equipment amounted to roughly 17 million MSEK during the quarter. You will not see any such investments during the rest of 2024. We will see a promising future sales development with our innovative products, high market growth, a very professional commercial organization, and some of the best commercial partners. At the moment we do not see anything that can change this. Of course, we may have single quarters that will not perform that well, but the trend is crystal clear. Sales are increasing much, and most quarters will be record quarters. High volumes will deliver high profit margins, even if we were affected in Q1 by our move to the new facility. The yellow bars show quarterly sales, and the orange line shows quarterly gross margins. With that, I will hand over to Kipling, our chief commercial officer, and he will give you a commercial outlook.

Theis Kipling
12:01 - 21:38

Thank you for waiting. I'm very pleased to be adding some more context to the decisive commercial successes that we've had here during Q1. In fact, I'm calling in from Atlanta in the US, where I'm here meeting with new customers, as well as reviewing the impressive growth plan that we have for North America together with our great US team. As Fredrik already mentioned, we are commercializing through four channels. And I want to give you a little bit of perspective here. The first channel is our direct sales. For established markets where we have our own team and our own device or legal entity. Our direct sales will continue to increase, although we expect the share versus total sales to likely reduce gradually due to increased utilization of partnerships. Because partnerships are our second channel, and the revenues coming from partnerships will grow faster than any other channel that we have. As we increase the number of partnerships. Partnerships are typically exclusive. It's a broader and very attractive collaboration. And today we have one partner, as already mentioned, being One Lambda, a part of Thermo Fisher. But we do expect many, several more to come. Our third channel is our lab services. Utilizing our IVDR-certified laboratory, which is a strong platform for continued growth. We do both patient testing on our own products. On behalf of other companies. And not least, do we pursue projects together with pharmaceutical companies. Our fourth channel is the distributor channel. Today we have, as mentioned, about 50 distributors, which is a number that actually has increased a lot during the past two years. Distributor contracts can be both exclusive and non-exclusive, and are typically used for us to enter a new geographic market. And once we see a large enough demand in a distributor market, we typically convert that market to become a direct sales market. Our agreement with One Lambda is progressing. Plan, and we are very pleased with both their progress and our collaboration. At least once per quarter. We have a face-to-face joint steering committee meeting with the management on both sides. But currently, we're actually meeting a lot more often. Our test for solid organ transplantation. The cfDNA was initially launched focused just on kidney as an indication. However, during 2024 we are broadening the intended use to also include heart, liver, and lung transplants. Significantly expand the market simply by the increased number of patients that our test can reach and help, which we are very excited about. In addition, we have two new. Rather substantial new product launches coming up, and we are currently in dialogue with One Lambda about these, and they may become part of the existing contract that we have with them. All in all, it's a very, very positive story, and I'm confident to say that we have a lot more to be said within this market during the coming years. Now on to our Devyser Genomics laboratories here in Atlanta, which is our CLIA-certified laboratory. We have signed our first commercial contract with the UK-based company Cyted. Which came nicely to one. And has already communicated. This has the potential of generating up to 25 million Swedish kronor over the first two years. Currently, both our PhD and Cambridge tests have been validated in the lab. Well, we're still working on validating cfDNA, and our test for cystic fibrosis. As of April 29th, we hired a vice president of Market Access Reimbursement and Public Affairs here in the US, which we are very excited about, and I'm confident that you'll soon be hearing about the results from this capacity within our device team. During our Q4 earnings call, we mentioned the updated guidelines made for cystic fibrosis here in the US. Changing the guidelines from detecting 23 variants. And I'm happy to report as press release already that we have brought on our first larger account, the University of North Carolina (UNC), as we refer to it, with an estimated total order value of up to 10 million Swedish kronor over four years. And to give you some perspective on the significance of the market opportunity here in the US, then the UNC account has a volume of a few thousand tests annually in a market that we estimate to be holding approximately 1.4 million tests annually. In the United States. Some of you may already have picked up on the announcement on April 29th, made by the FDA on the long-awaited final rule around the regulation of laboratory-developed tests. As expected, the final rule is more or less consistent with the proposed rule communicated by the FDA on September 29th of 2023. So for Devyser, this was as expected. Just like in Europe, the FDA wants to increase patient safety by regulating the many non-regulated tests available here. Devyser is an advocate of increased patient safety, and thus we do embrace the change. And we also believe that Devyser is actually very well positioned based on our experience taking products to IVDR approvals already. The final rule on the Regulation of Laboratory Developed Tests is a heavy document covering 528 pages, and together with our consultants, we have gone through it over the past week and so far. Our conclusions are the following. There will be a phasing period of up to four years. It is expected that some suppliers. will challenge the suggested FDA rule, which may lead to further delays. Selling of device products is not expected to be affected in the short term. Over the long term, some of the device's products, depending on their risk class, may need FDA approvals, but that work has been ongoing at Devyser for quite some time. A cornerstone in our commercialization strategy is to be claim-based and differentiated across both Europe and the US, within IVD with FDA requirements. This is a change from how Devyser has been operating over the past two years. This means that we are investing more into clinical and regulatory programs than ever before, and we are already recognized as a leader within Europe today. Our IVD certification and the track record we have is an approach we are now also bringing to the US in this regard. We welcome the partnership as announced, with Illumina being a key component for us to commercialize on their platform as required by the FDA. A few words on the Illumina partnership and the agreement we press released earlier in Q1. This agreement enables us to develop and commercialize end-to-end solutions on the Illumina platform. The instrument has preset software that cannot be altered and thus is a guarantee for consistent reproducibility, a requirement by the FDA. For a smaller company like Devyser. This is a very significant achievement to strike such an agreement. As a global instrument provider, we're excited to see this grow even further during the coming years. We plan to have our transportation products and our product for cystic fibrosis become FDA approved as the initial ones. And with that, I give the word back to you.

Fredrik Alpsten
21:44 - 24:10

Thank you for that, Theis. At our earnings calls, we speak very much about the robust sales development we have and our earnings growth. We do not speak that much about the world-class. And I would say even world-leading development of products that are taking place in the company, and that is important for our future sales growth. As you may know, since the company was founded 20 years ago, we have developed, redesigned, and launched over 35 products. We expect this robust development to continue. We have more than 30 employees within development, and they are contributing significantly. Yes, over the last 12 months we have launched seven to eight new products. In addition to the work on upgrading products from IVD to IVDR that we did. In addition to that, of course, we expect to launch 5 to 10 new products in the next 6 to 8 months, including three for transplantation. In addition, we are investing significantly in our clinical group and we are running quite a few clinical studies at the moment. As you know, over the last two years we have taken some very important steps to build a global, fast-growing, highly profitable diagnostic company. As you also have heard, we are very optimistic about the future. We are focusing on North America and Europe. You can see where we are. All our sales channels, direct sales partners, and distributors. We are very glad that the investments in the US market have given results, and that Americans now represent 9% of our total revenue. I'm also very proud of the work at the company, which year after year, can develop and launch many new innovative products. I'm optimistic and excited about some very interesting product launches within the next 6 to 18 months. However, as important as high growth is, continuing our path to profitability is our main focus in 2024. So with that, I now open up for questions.

Operator
24:15 - 24:41

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Ulrich Ratner from Carnegie. Please go ahead.

Unknown 1
24:43 - 25:52

Thank you very much. And good morning to you all. And a few questions on my end. And perhaps we will start off with the regulatory change in the US regarding lab-developed tests as being more of a stringent take on the industry by the FDA. And just a follow-up on the comments from you there, in regards to how much of your current work that you've done for IVDR can be recognized in the US as well, given the regulatory change, are you planning to accelerate FDA approval of certain tests in the US? And I recognize your collaboration with Illumina and their platform being one of the very few to be approved by the FDA. Which then in turn, I guess, would enable you to pursue FDA approval for certain tests. That would be my first question.

Fredrik Alpsten
25:53 - 25:55

Do you take that as yes?

Theis Kipling
25:55 - 26:20

Yes, I can do that. By saying that the Illumina equipment that we announced during Q1 was a deliberate and strategic intent to pursue FDA approvals. And that means that we are not letting this rule change anything, to be honest, in the way that we are working, we have a pretty ambitious plan. On the US and the FDA.

Fredrik Alpsten
26:25 - 26:31

And as we understand it all we get. Maybe I can add that we were expecting this. So this is not a surprise. Ross.

Unknown 1
26:33 - 27:04

And just to follow up, did you, but do you expect this to carry any additional cost on your end? Um, I know that you've undertaken measures already in terms of, uh, quality assurance and regulatory buildup internally. Uh, but will this require you to accelerate these processes that you've already implemented, or do you feel that your current operations are already scaled to a sufficient level?

Fredrik Alpsten
27:05 - 27:33

I can answer that. Yes, but we do not expect any higher expenses due to this. We can use some of our studies from Europe. We may need to run one or two small studies in the US to fulfill some requirements for the US market, but we do not see any significant increase in expenses due to this because we are scaled up already for that and had planned for that already.

Unknown 1
27:35 - 28:12

Great. And just a follow-up here, sort of a follow-up on some comments. And then both you, Fredrik, as well. Uh, because I do also recognize cystic fibrosis as an interesting marker there. Um, and your test appears to be competitive, but could you help us outline what is the current competitive profile of your tests and the competitors out there, and what is still sort of lacking before we see? All of this work that you've done translating into commercial contracts.

Fredrik Alpsten
28:13 - 28:15

Maybe you can answer that, Tyson.

Theis Kipling
28:15 - 29:26

Yeah, I can do that. Um, so the cystic fibrosis test that we have, uh, is one of a handful of tests here in the US that meets the guidelines and the changes to the guidelines, and that in itself should speak well for the potential that we see here with this test. Uh, and it goes together with the competitive challenge or improvement and the precision we achieve with how all our tests are made with regards to the workflow. So we know that our workflow across our tests within NGS integrates much more seamlessly and is favored by customers. And now we have this cystic fibrosis test with that unique workflow, plus being covered by the guidelines. Right, as only one of, I think, five here in the market, roughly, who actually does that? So, uh, we do expect a lot. Where we are, we are exploiting this opportunity here in the US. Day in, day out, all week. Right.

Unknown 1
29:26 - 29:55

And just a follow-up question on cystic fibrosis. Um, you've historically showcased the workflow benefits in MIA and in RHD screening. So just by comparison here, uh, how does your test on the workflow stack up to the current competition for those who are actually in line with the new guidelines?

Theis Kipling
29:56 - 30:36

On the workflow, I'd say we're still in the lead. Uh, that's typically one of the realizations whenever we convert customers to our tests, they, uh, when we break for lunch, after having done the demo, they ask, 'now what?' What do we do now? And we tell them we're done. Now we wait for the results, and they're completely relieved. That also applies to the cystic fibrosis test here in the US. And I'm super confident, you know, this is going to carry its weight. And we will be very successful in the States as we are successful with both cystic fibrosis and thalassemia and so forth. Uh, here and in Europe as well.

Unknown 1
30:37 - 31:17

Okay, great. And, uh, if we keep our focus on the North American markets, um, obviously sales are growing from a low base. And we're still awaiting delivery on the Canada tender. Uh, so what's the current update on delivering the already awarded tender? And I know from the last call that you were very optimistic in the short term that there would be an outcome in a larger tender from Blood Canada. Um, which you, you obviously are favorably positioned towards. Any update on that as well? Would be helpful.

Theis Kipling
31:19 - 31:20

Yeah, I can take that.

Fredrik Alpsten
31:20 - 31:20

Uh.

Theis Kipling
31:21 - 32:16

We believe that we still have the only, uh, test that is approved by Health Canada, which is itself quite a strong position to be in. We are communicating with the different providers. Or in various dialogues actually focused on RCG in Canada. So I remain very hopeful that this is going to be a great test covering most of Canada, as we are doing in the Nordics. We're covering all of Wales with our tests and I'm, you know, this will extend into Canada I am confident. And saying, I have high belief that this is going to be a pretty interesting and unique test and opportunity in the United States, even. But that said, we are still awaiting the already awarded tender to start taking effect. They are still in their internal preparations.

Unknown 1
32:18 - 32:22

Okay. So most likely towards the year end where we should see first deliveries.

Theis Kipling
32:23 - 32:29

Yeah, yeah, maybe you can comment on that project, but that's. That's a reasonable timeline.

Fredrik Alpsten
32:29 - 32:54

Yeah. That's what we have communicated earlier. It's not due to us that it has been delayed starting the already awarded tender, but we expect something around year end. And I would say and hopefully, as I said, we believe that the new and much bigger center that we are working on right now, we can share more about that at the next earnings call. Great.

Unknown 1
32:55 - 33:41

Um, two more questions, uh, from me, and I'll get back into the queue. Um, you talked about a bit of a softer market in Asia and Europe, and I know that you're seeing. That at least you're commenting very positively on market recovery. And yes, I know that you're adding distributors in Asia as one leading indicator, but could you help us sort of understand what you are using as your leading indicator on recovery in Europe? And is this mainly an external market thing, or are there any internal limitations?

Fredrik Alpsten
33:43 - 33:44

Can you comment on that?

Theis Kipling
33:45 - 35:24

Yes, I can cover that. So let's start in APAC. As I already mentioned, we have actually onboarded quite a number of distributors. And we're seeing, I'd say, pretty strong growth. Some of those are really coming on board quite fast and quite strong. So, this will rebound for sure. That said, APAC is, for now, less of a priority for Devyser. We're investing and focusing. I'd say the vast majority of our efforts are in Europe and North America. And then I can turn the focus to Europe. I think we're still seeing quite strong growth in Europe. But as we said, we obviously expect that to only increase and strengthen. And that's due to, you know, we're still in the very early days of going live with our type. Other countries that we have in Europe include Spain, France, the UK, Benelux, and the Germany region, as we referred. We are adding more people also during the year and we will see an increased effect from those. And our ambition is to replicate what we have done very successfully in Italy for the past years in all the large European markets. And I'm saying that we always believe because I know that we are competitively very strong, we are very well positioned and we when we go up against competitors. We usually win those demonstrations as well. So, I'm confident.

Unknown 1
35:25 - 35:57

But is there any market in Europe where you are not really satisfied with the development? I know that you've been awarded tenders out of the UK. Italy has been your largest market. I'm guessing it still is your largest market in Europe. And overall, looking at larger geographies such as Germany and France. Are you happy with the current development in direct sales in these regions, or are additional efforts needed to accelerate these markets?

Theis Kipling
35:58 - 36:02

So the only limitation... Yeah, you want the first one, but...

Fredrik Alpsten
36:02 - 36:06

Maybe you can comment a bit about French political advertising.

Theis Kipling
36:06 - 37:17

Yes, in France we are adding our first employee now. So in France, that's a market that we haven't really unlocked yet. That is only starting now. And with that, we will see the impact of it during next year. Initially, there will be some coming in this year. We see France as a great opportunity. We have done well in Germany. And we are far from done. Right. So, working with the team, we internally have a top-line aspiration for all of our markets here in the coming years. In Europe. Right. So, additionally in Spain, we have made some incremental gains and engaged in some new partnerships. I have high expectations that this is going to unleash and unlock additional growth. Regarding the UK. Did you see the Wales Centre announcement that we made with RHD? I am confident, and obviously, I'm ambitious. I would like things to move even faster. But when I look at what we have done in the past couple of years, I can only be very pleased. And I am.

Fredrik Alpsten
37:19 - 37:44

And maybe I can also add that we are still growing quite a lot in Italy, even if it's our biggest market. As we saw for 2023, we had a growth in excess of 20% in Italy, where we are market leaders for many products. We have also seen where we will not share the numbers here for Q1, but I will say this: Italy has done great in terms of revenue growth this year. Okay, great.

Unknown 1
37:45 - 38:23

And one last question on my end. This relates to the cost base. Can you help us understand how confident you are in achieving high margins here in line with your financial targets, although it spans a few years? But can you help us understand the costs of one-off character here in Q1 attributed to new facilities, ERP systems, and CRM systems? How much of your current cost base is considered one-off character?

Fredrik Alpsten
38:24 - 39:38

We have not shared the exact number because it also reflects how you define these expenses. Some are due to expanding production capacity and some are due to moving to the new facility. But it's important to remember what we stated already in the Q3 2023 report: we had higher expenses in Q4 and some higher expenses in Q1 2024. We do not foresee any such switching expenses going forward. So I think we have taken more or less all of that during the first quarter and the fourth quarter. As we have communicated earlier, we have double rent, for example, for the full 2024 so that's something we have to live with. But that's to minimize the risk of problems if we have delays moving. So we have taken that as a cost. And I'm sorry I didn't give you exact numbers here. But I'll stop here.

Unknown 1
39:39 - 40:05

And just a quick follow-up on that one. If we were to have excluded, I know that you don't want to define one-off costs, but if you were to exclude the things that you would consider one-off costs, would we have seen a linear trajectory like we did from Q1 to Q3 last year in terms of earnings improvements?

Fredrik Alpsten
40:06 - 40:56

Probably, as we saw here in Q1, it's important to remember we had a quite high decrease in the gross margin. And that, of course, is mainly because we have now used consultants for validating our new site. And that's expensive. Even if you add one, two, or three million in consulting costs with revenue of 50 million, it suddenly decreases the gross margin quite substantially. But yes, by adding a couple of consultants. But that's a one-time cost. We do not expect to see that going forward. Okay. Great.

Unknown 1
40:57 - 41:01

I'll get back into the queue. Thank you for taking my questions.

Fredrik Alpsten
41:01 - 41:01

Thanks.

Operator
41:07 - 41:12

The next question comes from Oskar Bergman from Redeye. Please go ahead.

Unknown 2
41:13 - 41:39

You guys, just have three short questions. The first one relates to the US pipeline, and I'm wondering if it's likely that a contract such as the one with Cyted, if that is likely to yield similar-sized contracts during the year, or if that was more of an exceptionally high order value for such a contract.

Fredrik Alpsten
41:40 - 41:42

You want the answer to that?

Theis Kipling
41:43 - 42:09

Yes, I can say that without making any promises of whether we will get similar contracts like the one we have with Cyted during the year. I can say that we are actively pursuing it and actively taking inquiries for potential new collaborations. So it is a part of how we are operating and utilizing our lab here in the US.

Unknown 3
42:10 - 42:11

Okay. Okay.

Unknown 2
42:12 - 42:32

And I'm wondering about the European market also because I think roughly half of your sales come from Italy. Right. And, um, as for the other large European markets. How did it differ from Italy in that sense, or is it more or less a similar playing field?

Theis Kipling
42:34 - 43:30

I can. I can answer that, but maybe, um. That's much the same. I mean, it's all within Europe. Italians are obviously different from Germans or French people, but they still work under the same regulation. It's very much the same. Right. And that being said, I do believe we will be able to do the same as we have done. A key differentiation is that we have a very significant Dutch team that is a great team in Italy. But the products are the same. Customer types are the same. So, I do believe that we are able to replicate what we have done in Italy and I believe that. In our Q4 earnings call, when we look at the growth trajectory we have, for example, in Germany and other markets, it does look like we are about to replicate what we have done in each of them.

Unknown 2
43:31 - 43:45

Okay. Thanks. And just a final question. There were some investments related to moving to new premises in Q1. Are those finished now or could we expect some additional investments in Q2?

Fredrik Alpsten
43:46 - 43:59

They are more or less finished now. So we will not see such a huge investment anymore. I cannot promise, but maybe we will buy 1 or 2 instruments. But we took much smaller amounts.

Unknown 2
44:00 - 44:02

All right, all right. Thanks. That's all for me. Thanks.

Unknown 3
44:04 - 44:04

Thank you.

Operator
44:10 - 44:33

As a reminder, if you wish to ask a question, please dial Pound Key five on your telephone keypad. There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.

Fredrik Alpsten
44:35 - 44:53

Thank you for participating and for your good questions. Looking forward to meeting you again. This time we will publish the Q2 report already in July, so hope to meet you there. And as always, do not hesitate to reach out if you have a more specific question.

Unknown 3
44:55 - 44:56

Thank you.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…